Please assess the completion status of the following clinical trial:

Trial Title: Histrelin Subcutaneous Implant in Children With Central Precocious Puberty

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-treated or treatment naive patients with gonadotropin-dependent precocious puberty~* Pre-treatment pubertal type response of LH to a stndard GnRH stimulation test before initiation of treatment~Exclusion Criteria:~* Children who are less than 2 years of age at enrollment~* Children whose chronological age is greater than 8 years (naive) and 10 years (pre-treated) for girls or 9 years (naive) and 11 years (pre-treated) for boys at the onset of the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Histrelin Subcutaneous Implant (50 mg) (Type: EXPERIMENTAL): Subcutaneous implant designed to deliver histrelin continously for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).